Related Experiment Videos

[A therapeutic protocol with cefoperazone in bronchopneumopathy in mucoviscidosis]

A Manca1, R Giannuzzi, S Mazzei

  • 1Istituto Policattedra di Pediatria Clinica e Sociale, Università degli Studi di Bari.

La Clinica Terapeutica
|December 15, 1990
PubMed

Insights

Cefoperazone showed favorable therapeutic efficacy in treating Pseudomonas aeruginosa respiratory infections in children with cystic fibrosis. While symptoms improved, the bacteria were not fully eradicated.

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pediatrics

Context:

  • Cystic fibrosis (CF) patients exhibit increased susceptibility to chronic bronchial infections, particularly by Pseudomonas aeruginosa.
  • Pseudomonas aeruginosa infections significantly contribute to morbidity and mortality in cystic fibrosis.

Purpose:

  • To evaluate the therapeutic efficacy of cefoperazone in treating Pseudomonas aeruginosa respiratory infections in pediatric cystic fibrosis patients.

Summary:

  • An open, noncomparative study assessed cefoperazone in 25 children with cystic fibrosis and Pseudomonas aeruginosa respiratory infections.
  • Favorable results were observed, with marked improvement in infection-specific symptoms and overall patient condition.
  • Complete eradication of Pseudomonas aeruginosa was not achieved, indicating a need for further treatment strategies.

Impact:

  • Cefoperazone offers a beneficial treatment option for managing Pseudomonas aeruginosa infections in pediatric cystic fibrosis, improving clinical outcomes.
  • The findings highlight the challenges in complete bacterial eradication and suggest potential areas for future research in cystic fibrosis treatment.

Related Concept Videos